INGN
BEARISH
$6.33
Live
Inogen, Inc. · NASDAQ
Target $12.67
(+100.1%)
$5.34
52W Range
$9.13
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$172.38M
P/E
N/A
ROE
-12.4%
Profit margin
-6.5%
Debt/Equity
0.09
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
INGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position with a Current Ratio of 3.12 and very low debt (D/E 0.09), it is unable to translate this into profitability, as evidenced by negative operating margins and stagnant revenue growth of 2%. There is a stark disconnect between the 'Strong Buy' analyst consensus and the fundamental reality of a 5-year price collapse of 88.6%. The stock currently presents as a classic value trap, trading below book value but lacking the growth catalysts necessary for a reversal.
Key Strengths
Very low leverage (Debt/Equity 0.09)
Strong short-term liquidity (Current Ratio 3.12)
Healthy Gross Margin (44.24%)
Trading at a discount to book value (P/B 0.90)
Consistent ability to beat lowered earnings estimates
Key Risks
Critical operational failure (Piotroski F-Score 1/9)
Stagnant top-line growth (YoY Revenue Growth 2.00%)
Persistent net losses and negative ROE (-12.43%)
Severe long-term capital erosion (-88.6% 5-year change)
Bearish technical trend (0/100 score)
AI Fair Value Estimate
Based on comprehensive analysis
$5.8
-8.4% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
21
Weak
45
20
10
30
0
AI Verdict
High Risk / Value Trap
Key drivers: Piotroski F-Score 1/9, Negative Forward P/E, Stagnant Revenue Growth, Extreme 5-year price decline
Confidence
90%
Value
45/100
Trades below book value, but lacks earnings to support a Graham Number calculation.
Positives
- P/S of 0.49 is very low
- P/B of 0.90 suggests asset-based value
Watchpoints
- Negative earnings render P/E metrics useless
- Lack of growth suggests the 'value' is eroding
Future
20/100
Growth metrics are insufficient to justify a bullish outlook.
Positives
- Analyst target price ($12.67) suggests potential upside
Watchpoints
- Revenue growth is nearly flat (2%)
- Forward P/E remains negative
Past
10/100
Historical price performance is overwhelmingly bearish.
Positives
- Recent quarterly beats on EPS estimates
Watchpoints
- Catastrophic 5-year return (-88.6%)
- Consistent trend of negative earnings
Health
30/100
Balance sheet is solvent, but the business model is operationally failing.
Positives
- Low Debt/Equity
- High Quick Ratio (2.52)
Watchpoints
- Piotroski F-Score 1/9 indicates failing operational health
- Negative ROA and ROE
Dividend
0/100
Non-dividend paying stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$6.33
Analyst Target
$12.67
Upside/Downside
+100.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for INGN and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
INGN
Inogen, Inc.
Primary
|
-88.6% | -52.4% | -10.6% | -22.4% | +1.6% | +1.9% |
|
DERM
Journey Medical Corporation
Peer
|
-50.0% | +251.1% | -28.9% | -34.4% | -38.3% | +5.5% |
|
ACH
Accendra Health, Inc.
Peer
|
-92.8% | -89.2% | -85.8% | -73.2% | -22.1% | -16.3% |
|
HRTX
Heron Therapeutics, Inc.
Peer
|
-94.8% | -68.8% | -53.1% | -33.4% | -12.1% | +6.6% |
|
ARCT
Arcturus Therapeutics Holdings Inc.
Peer
|
-87.2% | -57.7% | -51.9% | -61.4% | -9.7% | -6.0% |
ING
Inogen, Inc.
Primary
5Y
-88.6%
3Y
-52.4%
1Y
-10.6%
6M
-22.4%
1M
+1.6%
1W
+1.9%
DER
Journey Medical Corporation
Peer
5Y
-50.0%
3Y
+251.1%
1Y
-28.9%
6M
-34.4%
1M
-38.3%
1W
+5.5%
ACH
Accendra Health, Inc.
Peer
5Y
-92.8%
3Y
-89.2%
1Y
-85.8%
6M
-73.2%
1M
-22.1%
1W
-16.3%
HRT
Heron Therapeutics, Inc.
Peer
5Y
-94.8%
3Y
-68.8%
1Y
-53.1%
6M
-33.4%
1M
-12.1%
1W
+6.6%
ARC
Arcturus Therapeutics Holdings Inc.
Peer
5Y
-87.2%
3Y
-57.7%
1Y
-51.9%
6M
-61.4%
1M
-9.7%
1W
-6.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-20.42
PEG Ratio
N/A
P/B Ratio
0.9
P/S Ratio
0.49
EV/Revenue
0.2
EV/EBITDA
-7.36
Market Cap
$172.38M
Profitability
Profit margins and return metrics
Profit Margin
-6.52%
Operating Margin
-12.21%
Gross Margin
44.24%
ROE
-12.43%
ROA
-6.35%
Growth
Revenue and earnings growth rates
Revenue Growth
+2.0%
Earnings Growth
N/A
Q/Q Revenue Growth
+2.05%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.09
Low debt
Current Ratio
3.12
Strong
Quick Ratio
2.52
Excellent
Cash/Share
$4.39
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
43.1%
Op. Margin
-11.4%
Net Margin
-8.7%
Total Assets
$0.3B
Liabilities
$0.1B
Equity
$0.2B
Debt/Equity
0.55x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
352%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-24
$-0.26
+26.8% surprise
2025-11-05
$-0.02
+77.8% surprise
2025-08-07
$-0.02
+77.8% surprise
Healthcare Sector Comparison
Comparing INGN against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-12.43%
This Stock
vs
-46.09%
Sector Avg
-73.0%
(Below Avg)
Profit Margin
-6.52%
This Stock
vs
-19.58%
Sector Avg
-66.7%
(Weaker)
Debt to Equity
0.09
This Stock
vs
4.1
Sector Avg
-97.8%
(Less Debt)
Revenue Growth
2.0%
This Stock
vs
88.16%
Sector Avg
-97.7%
(Slower)
Current Ratio
3.12
This Stock
vs
3.58
Sector Avg
-12.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
INGN
Inogen, Inc.
|
BEARISH | $172.38M | - | -12.4% | -6.5% | $6.33 | |
|
DERM
Journey Medical Corporation
|
BEARISH | $164.62M | - | -44.0% | -18.5% | $4.95 | Compare |
|
ACH
Accendra Health, Inc.
|
BEARISH | $163.2M | - | -196.4% | -12.4% | $2.11 | Compare |
|
HRTX
Heron Therapeutics, Inc.
|
BEARISH | $160.82M | - | -% | -13.0% | $0.85 | Compare |
|
ARCT
Arcturus Therapeutics Holdings Inc.
|
BEARISH | $189.87M | - | -28.9% | -80.2% | $6.68 | Compare |
INGN
Inogen, Inc.
BEARISH
Mkt Cap
$172M
P/E
-
ROE
-12.4%
Price
$6.33
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | BOURQUE MICHAEL J | Chief Financial Officer | Stock Award | 29,749 | $5,331 |
| 2026-02-27 | BOURQUE MICHAEL J | Chief Financial Officer | Stock Award | 42,007 | - |
| 2026-02-27 | RAMADE GREGOIRE | Officer | Stock Award | 13,005 | - |
| 2026-02-27 | SMITH KEVIN RAYMOND MERRILL | Chief Executive Officer | Stock Award | 33,410 | $4,178 |
| 2026-02-27 | SMITH KEVIN RAYMOND MERRILL | Chief Executive Officer | Stock Award | 58,346 | - |
| 2026-02-27 | SMITH KEVIN P. | General Counsel | Stock Award | 1,500 | $9,150 |
| 2026-02-27 | SMITH KEVIN P. | General Counsel | Stock Award | 14,005 | - |
| 2026-02-27 | YI BOYER JENNIFER M | Officer | Stock Award | 3,603 | - |
| 2026-02-27 | YI BOYER JENNIFER M | Officer | Stock Award | 25,017 | - |
| 2026-02-27 | WRIGHT MARY E | Officer | Stock Award | 2,851 | $9,150 |
| 2026-02-27 | WRIGHT MARY E | Officer | Stock Award | 7,506 | - |
| 2025-12-01 | RAMADE GREGOIRE | Officer | Stock Award | 31,566 | - |
| 2025-12-01 | SMITH KEVIN RAYMOND MERRILL | Chief Executive Officer | Stock Award | 28,334 | - |
BOURQUE MICHAEL J
Chief Financial Officer
2026-02-27
29,749 shares
·
$5,331
BOURQUE MICHAEL J
Chief Financial Officer
2026-02-27
42,007 shares
RAMADE GREGOIRE
Officer
2026-02-27
13,005 shares
SMITH KEVIN RAYMOND MERRILL
Chief Executive Officer
2026-02-27
33,410 shares
·
$4,178
SMITH KEVIN RAYMOND MERRILL
Chief Executive Officer
2026-02-27
58,346 shares
SMITH KEVIN P.
General Counsel
2026-02-27
1,500 shares
·
$9,150
SMITH KEVIN P.
General Counsel
2026-02-27
14,005 shares
YI BOYER JENNIFER M
Officer
2026-02-27
3,603 shares
YI BOYER JENNIFER M
Officer
2026-02-27
25,017 shares
WRIGHT MARY E
Officer
2026-02-27
2,851 shares
·
$9,150
WRIGHT MARY E
Officer
2026-02-27
7,506 shares
RAMADE GREGOIRE
Officer
2025-12-01
31,566 shares
SMITH KEVIN RAYMOND MERRILL
Chief Executive Officer
2025-12-01
28,334 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
3 analysts
Freedom Broker
2026-04-07
Buy
Past News Coverage
Recent headlines mentioning INGN from our newsroom.
Newest → oldest
No matching news yet.